Adverse Events of Interest Following Influenza Vaccination in the First Season of Adjuvanted Trivalent Immunization: Retrospective Cohort Study
Authors:
- Simon de LusignanSimon de Lusignan
- Ruby S M TsangRTRuby S M Tsang
- Oluwafunmi AkinyemiOAOluwafunmi Akinyemi
- Jamie Lopez BernalJBJamie Lopez Bernal
- Gayatri AmirthalingamGAGayatri Amirthalingam
- Julian SherlockJSJulian Sherlock
- Gillian SmithGSGillian Smith
- Maria ZambonMZMaria Zambon
- Gary HowsamGHGary Howsam
- Mark JoyMJMark Joy
Open Access
- 28 March 2022
- journal article
- research article
- Published by JMIR Publications Inc. in JMIR Public Health and Surveillance
- Vol. 8 (3) , e25803
Abstract
Background: Vaccination is the most effective form of prevention of seasonal influenza; the United Kingdom has a national influenza vaccination program to cover targeted population groups. Influenza vaccines are known to be associated with some common minor adverse events of interest (AEIs), but it is not known if the adjuvanted trivalent influenza vaccine (aTIV), first offered in the 2018/2019 season, would be associated with more AEIs than other types of vaccines. Objective: We aim to compare the incidence of AEIs associated with different types of seasonal influenza vaccines offered in the 2018/2019 season. Methods: We carried out a retrospective cohort study using computerized medical record data from the Royal College of General Practitioners Research and Surveillance Centre sentinel network database. We extracted data on vaccine exposure and consultations for European Medicines Agency–specified AEIs for the 2018/2019 influenza season. We used a self-controlled case series design; computed relative incidence (RI) of AEIs following vaccination; and compared the incidence of AEIs associated with aTIV, the quadrivalent influenza vaccine, and the live attenuated influenza vaccine. We also compared the incidence of AEIs for vaccinations that took place in a practice with those that took place elsewhere. Results: A total of 1,024,160 individuals received a seasonal influenza vaccine, of which 165,723 individuals reported a total of 283,355 compatible symptoms in the 2018/2019 season. Most AEIs occurred within 7 days following vaccination, with a seasonal effect observed. Using aTIV as the reference group, the quadrivalent influenza vaccine was associated with a higher incidence of AEIs (RI 1.46, 95% CI 1.41-1.52), whereas the live attenuated influenza vaccine was associated with a lower incidence of AEIs (RI 0.79, 95% CI 0.73-0.83). No effect of vaccination setting on the incidence of AEIs was observed. Conclusions: Routine sentinel network data offer an opportunity to make comparisons between safety profiles of different vaccines. Evidence that supports the safety of newer types of vaccines may be reassuring for patients and could help improve uptake in the future.Keywords
All Related Versions
This publication has 26 references indexed in Scilit:
- Evaluation of the first pharmacist-administered vaccinations in Western Australia: a mixed-methods studyBMJ Open, 2016
- Self controlled case series methods: an alternative to standard epidemiological study designsBMJ, 2016
- Royal College of General Practitioners Research and Surveillance Centre (RCGP RSC) sentinel network: a cohort profileBMJ Open, 2016
- Risk of anaphylaxis after vaccination in children and adultsJournal of Allergy and Clinical Immunology, 2016
- ggplot22016
- Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjectsVaccine, 2014
- Safety of MF59-Adjuvanted Influenza Vaccination in the Elderly: Results of a Comparative Study of MF59-Adjuvanted Vaccine Versus Nonadjuvanted Influenza Vaccine in Northern ItalyAmerican Journal of Epidemiology, 2013
- The methodology of self-controlled case series studiesStatistical Methods in Medical Research, 2009
- Tutorial in biostatistics: the self‐controlled case series methodStatistics in Medicine, 2005
- Oculo‐respiratory Syndrome: A New Influenza Vaccine–Associated Adverse Event?Clinical Infectious Diseases, 2003